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Nu-3 [butyl-phosphate-5 -thymidine-3 -phosphate-butyl] is a modiﬁed nucleotide that has been shown to have antimicrobial
activity against a range of bacteria including Pseudomonas aeruginosa. However, data on the toxicological proﬁle of Nu-3 are still
lacking. In the present study, the toxicity of Nu-3 was evaluated by the following studies: acute oral toxicity, dermal and mucous
membraneirritation,multiple-dosetoxicityandgenotoxicityinvivoandvitro.TheacuteoraltoxicitytestinmiceshowedthatNu-
3h a da nL D 50 of 2001mg/kg body weight. The irritation tests on rats revealed that Nu-3 was not irritant, with an irritation scoring
of 0. The multiple-dose toxicity study in rats showed that Nu-3 did not cause signiﬁcant changes in histology, selected serum
chemistry, and hematological parameters compared to the controls. Rats administrated with multiple-doses of Nu-3 showed no
visible toxic symptoms. Both in vitro and in vivo, Nu-3 exhibited no notable genetic toxicity. Overall, the data suggest that Nu-
3 is hypotoxic or nontoxic antimicrobial compound that warrants being further developed for treating Pseudomonas aeruginosa
infection.
1.Introduction
Pseudomonas aeruginosa has become the most common
gram-negative bacterial species associated with serious
hospital-acquired infections [1, 2]. Mortality rates outbreaks
from P. aeruginosa in burn units can be signiﬁcantly high
(60%) [3]. Immediate use of eﬀective antimicrobial therapy
for P. aeruginosa bacteremia has been shown to signiﬁcantly
reduce mortality [4]. However, the intrinsic resistance of P.
aeruginosatomanyantimicrobialagentsand,inaddition,the
variety of their increasingly recognized acquired resistance
mechanisms make their management in the hospital setting
problematic [5]. Of great concern is the growing emergence
of multidrug-resistant (MDR) strains of P. aeruginosa [6–
9], and the severity of associated infections. Unfortunately,
the development of new antibiotics with activity against
gram-negative organisms has not kept pace with the increase
in prevalence of multidrug resistant pathogens. To provide
clinicians with credible alternative treatments to reduce the
increasing human mortality and morbidity associated with
the infectious diseases by drug-resistant bacterial pathogens,
there is a compelling need to develop new therapeutic agents
that are eﬀective against drug-resistant mutants [10].
Nubiotics are a novel class of modiﬁed nucleotides-based
antimicrobial agents. Structurally, nubiotics are synthetic
nucleotides and oligonucleotides with nuclease-resistant
backbones, and are fully protonated. Although the exact
mechanisms of antibiotic actions for nubiotics are not totally
understood,theyarethoughttobeindeeddiﬀerentfromthat
of the traditional antimicrobial drugs and the protonated
structures are believed, in part, to make nubiotics to be taken
up by bacterial cells more easily. As a family, nubiotics has
many members, including Nu-2, Nu-3, Nu-4, and Nu-5,
which have been shown to have eﬀective therapeutic eﬀect
in the burn wound Pseudomonas aeruginosa infection model
established in mice [11].2 Journal of Biomedicine and Biotechnology
Nu-3 [butyl-phosphate-5 -thymidine-3 -phosphate-
butyl] is a potent nubiotics that is a fully protonated
deoxynucleotide. The chemical structure of Nu-3 is shown
in Figure 1. The therapeutic eﬃcacy of Nu-3 against
pulmonary Pseudomonas aeruginosa infection was evaluated
in vivo animal model [11], in which liposome-encapsulated
Nu-3 presented eﬃcacious antibacterial activity.
To further assess Nu-3 as a potential new antibiotic for
topical uses, we performed studies for its acute, multiple-
dose dermal toxicity and the irritation to skin and eyes and
genetic toxicity. These studies have revealed that Nu-3 has
hypotoxicity at high dosage, and it has no chronic toxicity
and irritation. It was also revealed that Nu-3 does not have
notable genetic toxicity. This study provides solid data to
warrant further development of Nubiotics as a novel class
of antimicrobial agents for treating Pseudomonas aeruginosa
infection.
2.Materialsandmethods
2.1. Nu-3. Nu-3 was synthesized and puriﬁed at Oligos and
so forth, Inc. (Oregon) with 99.5% purity (HPLC).
2.2. Animals. Balb/c mice and Sprague-Dawley rats used
in this study were purchased from Beijing Vital River
Company. The body weight ranged from 17–20g for mice
and 250–300g for rats. All the test animals were randomized
into groups after being quarantined for 3–5 days before
experiments. Randomly, the body weight variation was
within ±20% of the mean weight in each sex. The animals
were housed in stainless mouse cages with sterile padding.
Food and water were aseptic and available adlibitum. All the
mice and rats were housed in a room with a temperature of
20–25◦C, a relative humidity of 40%–70%, and a 12-hour-
light/dark cycle. The use and care of the animals followed
theRegulationsfortheAdministrationofAﬀairsConcerning
Experimental Animals in China (11-14-1988).
2.3. Cells and Culture. Chinese hamster ovary cells (CHO
and CHO-K1) were purchased from Cell Culture Center,
Peking Union Medical University. CHO-K1cells were grown
in DMEM/F-12 supplemented with 10% fetal bovine serum
(FBS), 2mM L-glutamine, and penicillin-streptomycin
(100units/ml, 100μg/ml). Incubation was performed at
37◦C in a humidiﬁed atmosphere of 5% CO2 in air.
2.4. Intragastric Acute Toxicity Study in Mice. There were
ﬁ v em a l ea n dﬁ v ef e m a l em i c ep e rd o s eg r o u p .M i c ew e r e
intragastrically administered with a total dose of 2500,
1988, 1580, 1256, and 1000mg/kg/mouse of Nu-3 in saline
(Table 1) .T h ed o s i n gv o l u m e sw e r ea l l0 . 5 m l / m o u s e .A
control group received saline only. All the mice were
intragastricallyadministered with one dose. Micewere fasted
24h before given the test materials and were allowed to get
food and water adlibitum after intragastric administration.
Animals were observed for their death and subjected to a
gross necropsy immediately after they died until day 8, after
which the survivor were euthanized and subjected to a gross
necropsy and histopathology observation for toxicity. Livers
were removed and ﬁxed by 4% neutral formalin at room
temperature for 48h. The serial tissue sections at 5-μm-thick
were obtained after embedded in paraﬃn. Each slide was
stained with hematoxylin and eosin (H&E) then examined
under light microscopy (Olympus CX31). Throughout the
study,theclinicalsymptoms,neurologicalbehaviorandbody
weight were recorded daily.
2.5. T-Cell Proliferation Study in Mice after Being Intragastric-
Treated with Nu-3. T h r e em i c eo fc o n t r o l ,m a l ea n df e m a l e
groupweresacriﬁcedandtheirlymphocytesuspensionswere
prepared from the spleen on 24h after being intragastrically
administeredwithasingledoseofNu-3at100mg/kg/mouse.
Single-lymphocyte suspensions were incubated in triplicates
in 96-well plates at 2×105 cells/well, in RPMI-1640 plus 5%
of fetal calf serum (FCS) at 37◦Ci na5 %C O 2 incubator
and stimulated for 48h with 2μg/ml precoated anti-CD3
and 1μg/ml anti-CD28 (positive control), 2μg/ml of BSA
(irrelevant antigen), or no antigen (negative control). T-cell
proliferation was evaluated by Cell Titer 96 Aqueous Nonra-
dioactive Cell Proliferation Assay was performed according
to the manufacturer’s instruction (Promega, USA). The
mixture of MTS/PMS (20μle a c hw e l l )w a sa d d e dt oe a c h
well to develop the color. After 4h of incubation, the OD
values of plates were read at 490nm by a plate reader
(Magellan, Tecan Austria GmbH). Data were expressed as
stimulation index (SI), calculated as the mean reading of
triplicate wells of antigen stimulation, and divided by the
mean reading of triplicate wells of negative control.
2.6. Twenty-Eight-Day Dermal Toxicity Study in Rats. There
were ten rats in the treatment group (5 males; 5 females)
in which rats were treated with 50μl of 100mg/ml Nu-3 in
saline. The control group containing same number of rats
received saline only. Fur was clipped from dorsal area of the
trunk 24h prior to the test and was reclipped as necessary
to allow observation and dosing. The test materials were
applied on the shaved area and kept in contact with the help
ofnonirritating styptic plasterand porous gauzebandage.To
ensurethatlocalapplicationofNu-3remainedinthedorsum
of animals, the measure of fastening multiply was taken.
Brieﬂy, a band-aid was put on the liniment area, and then
covered a pad of medical gauze, followed by wrapping up
with gauze bandage. Rats were treated with the test materials
for 6h per day. At the end of 6 hours, any residual material
was gently removed from the treatment site using cotton bud
soaked in distilled water. Animals were treated in the way
described above everyday for 28 days. Cage side observation
was made daily, which included evaluation of the eﬀect on
skin, fur, eyes, and respiratory and neural behavior. By the
29th day half of the rats were euthanized and subjected
to a gross necropsy. Organs were taken out carefully and
weighted. The remaining animals were observed for further
14 days, and then they were euthanized, subjected to a gross
necropsy and organ weights recorded on day 43. During
the study, body weight, water and food consumption were
monitored according to the experimental design. BloodJournal of Biomedicine and Biotechnology 3
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Figure 1: Chemical structure of Nu-3.
Table 1: Dosing table for acute intragastric toxicity study of Nu-3 in mice.
Groups Treatment Dose∗ Drug conc. Dose vol. No. of animals
(mg/kg) (mg/ml) (ml/mice) Male Female
1 Nu-3 2500 87.35 0.5 5 5
2 Nu-3 1988 70.91 0.5 5 5
3 Nu-3 1580 56.35 0.5 5 5
4 Nu-3 1256 44.95 0.5 5 5
5 Nu-3 1000 34.39 0.5 5 5
∗Balb/c mice were intragastrically administered with a single dose of 2500, 1988, 1580, 1256,1000mg/kg/mouse of Nu-3 in saline.
samples were collected from the caudal vein of all the rats
weekly.
2.7.RatSkinandEyeIrritationTest. Tenratswereusedinthe
test. On the day prior to dosing, an area on the dorsal surface
of the skin was clipped free of hair. On the day of dosing,
the clipped areas in rats were lacerated to errhysis with sterile
pinheads. Then 10mg/ml Nu-3 in saline was applied to
the shaved area of ﬁve rats and the skin was covered with
nonirritating styptic plaster and porous gauze bandage. The
rats were then returned to their cages. After 6h of exposure
period, the coverings were removed and the test area was
rinsed with distilled water. The other ﬁve rats were used as
control and treated with saline. The rats were examined for
the presence of erythema and oedema according to a skin
irritation scoring standard at the intervals of 1, 24, 48, and
72h [12].
Rat eye irritation test was used to evaluate the degree
to the mucous irritation of Nu-3. Six rats were used for
this test and each animal served as its own control. 0.03ml
Nu-3 of 1mg/ml concentration with saline was dripped to
the left eyes of the rats, and 0.03ml saline was dripped to
the right eyes of the rats as control. All the measures were
taken to ensure that the test materials are dripped into the
conjunctival sac of the rats. The rats were examined for the
presence of changes in eyes according to the eye irritation
scoring standard at grading intervals of 1, 4, 24, 48, 72 and
96h. Then sum of scores calculated was classiﬁed according
to the eye irritation scoring standard [12].
2.8. In Vitro CHO/HGPRT Mammalian Cell Mutagenesis
Assay. The purpose of this study was to assess the ability of
Nu-3 to induce mutations at the HGPRT locus in cultured
mammalian cells. CHO-K1 cells were used for this assay.
Cultures were purged of preexisting mutants by growth for
2 days in DMEM/F-12 medium supplemented with 10%
FBS, 5×10−6 M thymidine, 1×10−5 M hypoxanthine, and
3.2×10−6 Maminopterin.Thetestwasperformedaccording
to the procedure of O’Neill and Hsie [13] and O’Neill et al.
[14, 15]. The cells which were purged of preexisting mutants
were treated for 4h with the test and control materials and
then allowed an expression time of 7–9 days; the cells were
then replated. After the period of expression of the mutant
phenotype, mutant colonies were selected in the following
manner. Each culture ﬂask was trypsinized and the cells
were seeded in new ﬂasks as follows: (a) 3 ﬂasks each with
200 cells and without the purine analogue 6-thioguanine;
( b )3ﬂ a s k se a c hw i t h2×105 cells and with 6-thioguanine
(10μg/ml). After 8 days, selection was determined by the
formation of colonies resistant to the purine analogue. Next,
the colonies were ﬁxed with methanol for 15min and stained
with Giemsa (Sigma) for 30min. Giemsa was poured oﬀ
and visible colonies were counted. Nu-3 was evaluated in
the presence and absence of a metabolic activation system4 Journal of Biomedicine and Biotechnology
derived from rat liver (S9). Dimethylbenzanthracene was
used in the positive control for the activated assay and
ethyl methanesulfonate was used in the positive control
for the nonactivated assay. Saline was the negative control.
The Nu-3 concentrations for the assay ranged from 500
to 2000μg/ml. The colony counts obtained were used to
calculate: (a) cloning eﬃciency (CE) in absolute values
(number of colonies formed divided by the number of cells
seeded); (b) the number of mutant colonies observed in each
treatment; (c) the absolute CE observed after selection; (d)
the mutation frequency (MF) (number of mutant colonies
divided by the number of clonable cells which was equal to
the number of cells seeded × the absolute CE after selection).
2.9. In Vivo Mouse Micronucleus Assay. Nu-3 was eval-
uated for its ability to induce micronuclei in the bone
marrow of Balb/c mice according to Hayashi et al. [16].
Cyclophosphamide (PC) was used as the positive control,
and saline was the negative control. Groups of ﬁve male
and ﬁve female Balb/c mice were dosed with Nu-3 at 250,
500, and 1000mg/kg on 2 consecutive days via intragastric
administration.Allthemicewereeuthanized6hafterthelast
dosing, andthebonemarrowwastakentomakesmear.Bone
marrow cells from animals were analyzed for the number of
polychromatic erythrocytes (PCEs) that contained at least
one micronucleus. A minimum of 2000 PCEs was analyzed
for the negative control, the positive control and for mice
treated with the Nu-3. The PCE fraction was determined
by counting a minimum of 200 erythrocytes (PCEs plus
normochromatic erythrocytes [NCEs]).
2.10.StatisticalAnalyses. Datawereexpressedasmeans±SD
and subjected to one-way ANOVA with factors of treatment,
genotype or wild type. Comparisons between two groups
were performed by unpaired Student’s t-test. A value of
P<.05 was considered signiﬁcantly diﬀerent.
3. Results
3.1. Acute Oral Toxicity in Mice. Mice were intragastrically
administered with a single dose of Nu-3 at 2500 (Group
1), 1988 (Group 2), 1580 (Group 3), 1256 (Group 4), and
1000 (Group 5)mg/kg/mouse (Table 1). Following the single
dose, ﬁve male and four female mice in Group 1, four female
in Group 2 died in 24 hours. One female in Group 2 and
one female in Group 4 died on day 1. From day 2 to day
8 none of the mice in all the groups died. According to the
mortality of each group, the minimum lethal dose (MLD)
was calculated to be 1256mg/kg. Clinical observations of
the dying mice attributed to the administration of Nu-3
werelethargy,tachypnea,andtremoranddisheveledclothing
hair. The surviving mice did not show any evident toxic
symptom in clinical observations. There were no treatment-
related eﬀects on mouse behavior in the cage and body
weight for males or females (data not shown). In the early
dead mice, some pathological changes were found, including
livers turning white and brittle with some yellowish brown
nidi, the change of the spleen surface into uneven with some
hemorrhagic spots, and kidneys showing some gray-white
focus on surfaces. It was also observed that there were some
damagesandhemorrhageingastricwallsandintestinaltracts
ofmicewhichdiedin5hoursafterbeingadministered.There
was no obvious pathological change at gross necropsy and
histopathological changes in liver for scheduled euthanasia
mice in the study (Figure 2).
3.2. T-cell Proliferation Study in Mice. To examine if the
administration of Nu-3 could aﬀect on immune system,
the spleen cells were used to test T-cell proliferation. As
shown in Figure 3, the treatment with Nu-3 had no impact
on proliferation of spleen T-cells stimulated with either
anti-CD28 (positive control) or BSA (irrelevant antigen)
compared with the cells from the nontreated mice. This data
suggested that Nu-3 had no toxic eﬀect on immune system.
3.3. Dermal Toxicity with 28-Day Repeated Doses in Rats.
Ratswereappliedwith50μlof100mg/mlNu-3(totaldoseof
250mg/kg/day) for 28 days. Cage side observation was made
t w i c ee v e r y d a y .T h e r ew e r en oe v i d e n tt o x i cs y m p t o m si n
both treated and control rats during observation time. Local
dermal irritation was not observed in all test rats. Control
and test rats showed a similar pattern of weight growth, food
and water uptake (Figure 4). Although there seemed to be
some lagging in water uptake in treated group compared to
control (Figure 4(b)), the body weight of test group seemed
to increase faster (Figure 4(a)). There were no treatment-
related changes on food uptake in treated rats compared to
the controls (Figure 4(c)). During the observation time after
administrating Nu-3 on the back of the body for 28 days,
there were no signiﬁcant diﬀerences between the treated and
control rats in the body weight gain although the treated rats
took less water and food compared to the controls.
All rats survived until scheduled necropsy. Surviving
animals were euthanized at day 29 and day 43. No obvious
pathological changes were found in all organs by gross
appearance. Moreover, there was no signiﬁcant diﬀerence
(P>.05) in the organ weight between the test groups and the
control group (Table 2).
The results of histopathological analysis of necropsy
samples on liver, kidney, spleen and skin of the body back
where Nu-3 was applied showed no signiﬁcant pathological
changes and toxic eﬀects except that there was a slight
increase in skin labrocytes of the treated rats in comparison
with the controls’. The microscopic examination revealed
that liver, kidney, and spleen were normal.
Hematology and selected serum chemistry analyses also
showed no signiﬁcant diﬀerences (P>.05) between control
and treated groups (Table 3).
3.4. Skin and Eye Irritation in Rats. After applied with Nu-3
onthedorsalsurface,theratswereexaminedforthepresence
of erythema and oedema on the test area according to a
skin irritation scoring standard [12]. The results showed that
the scores for erythema and oedema were 0 at 1, 24, 48,
and 72h after administration, which was the same to the
controls’. The eye irritation scores were recorded accordingJournal of Biomedicine and Biotechnology 5
(a) (b)
Figure 2: Histopathological observation of Nu-3 treated mice. (a) Livers from the control group. (b) Livers from the Nu1-3 treated group.
The hepatic structure is normal no histopathological changes were observed. Original magniﬁcation ×400.
Table 2: Absolute and relative organ weights of rats in 28-day dermal toxicity study of Nu-3.
Organs Nu-3∗ Saline
Day 29 Day 43 Day 29 Day 43
Liver
Absolute weight 17.40±18.13 16.33±13.14 15.96±1.40 18.73±0.57
Relative weight∗ 3.25±0.13 3.45±0.17 3.24±0.07 4.17±0.16
Spleen
Absolute weight 0.70±0.03 0.73±0.00 0.73±0.00 0.73±0.01
Relative weight 0.13±0.00 0.16±0.00 0.15±0.00 0.16±0.00
Kidney
Absolute weight 3.43±0.50 3.1±0.31 3.20±0.12 3.13±0.02
Relative weight 0.65±0.00 0.66±0.00 0.645±0.00 0.70±0.00
∗The concentration of Nu-3 was 100mg/ml. The relative weight was calculated as percentage of the organ to body weight. The data was expressed as average
±SD.
T cell proliferation
Naive Female Male
0
3
6
9
Anti-CD3/anti-CD28
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I
Figure 3: Analysis of T-cell proliferation in mice after being
intragastric treatment with Nu-3. Na¨ ıve, saline treated. Female: 3
female mice treated with Nu-3. Male: 3 male mice treated with Nu-
3. SI: stimulation index.
to the eye irritation scoring standard [12] at 1, 4, 24, 48, 72,
and 96h after administration, all of which were shown to be
0. Therefore, according to the skin and eye irritation scoring
standard, all the rats didn’t show any toxic symptom after
being given Nu-3. The treated skins and eyes were normal
compared to the controls.
3.5. CHO/HGPRT Mammalian Cell Mutagenesis. The muta-
tion frequency was assessed based on the number of mutants
per 1×106 clonable cells (Table 4). In the activated assay,
the mean mutation frequency was 3.3 for the saline neg-
ative control, 244 for the dimethylbenzanthracene positive
control, 5.4 for the 500μg/ml concentration of Nu-3; 4.5
for the 1000μg/ml concentration of Nu-3 and 6.9 for the
2000μg/ml concentration of Nu-3. In the nonactivated assay,
the mean mutation frequency was 3.3 for the saline negative
control; 187 for the ethylmethanesulfonate positive control,
4.5 for the 500 μg/ml concentration of Nu-3, 5.7 for the
1000μg/mlconcentrationofNu-3and8.3forthe2000μg/ml
concentration of Nu-3. These data suggested that Nu-3 was
not mutagenic in the testing system both in the activated and6 Journal of Biomedicine and Biotechnology
T
a
b
l
e
3
:
H
e
m
a
t
o
l
o
g
i
c
a
l
a
n
a
l
y
s
i
s
o
f
2
8
-
d
a
y
d
e
r
m
a
l
t
o
x
i
c
i
t
y
s
t
u
d
y
o
f
N
u
-
3
i
n
r
a
t
s
.
H
e
m
a
t
o
l
o
g
i
c
a
l
p
a
r
a
m
e
t
e
r
s
N
u
-
3
∗
S
a
l
i
n
e
7
1
4
2
1
2
8
3
5
4
2
7
1
4
2
1
2
8
3
5
4
2
(
d
a
y
s
)
W
B
C
(
1
0
9
/
L
)
1
3
.
3
6
±
1
2
.
1
1
5
.
3
±
1
8
.
4
1
1
.
8
2
±
2
.
8
1
2
.
4
8
±
9
.
1
1
3
.
0
0
±
6
.
8
1
7
.
0
0
±
2
7
1
1
.
1
4
±
3
.
0
1
4
.
5
7
±
1
3
.
9
1
2
.
5
2
±
3
.
9
1
2
.
1
3
±
4
.
6
1
3
.
0
0
±
1
7
1
7
.
5
0
±
3
.
3
R
B
C
(
1
0
1
2
/
L
)
6
.
8
5
±
0
.
6
1
1
.
3
6
±
0
.
9
9
.
7
8
±
1
.
8
6
.
9
3
±
0
.
1
6
.
0
7
±
0
.
1
9
.
2
4
±
1
.
1
6
.
7
0
±
1
.
3
1
1
.
7
±
1
.
4
9
.
9
7
±
2
.
8
6
.
9
2
±
0
.
1
6
.
7
1
±
0
.
1
1
0
.
1
1
±
1
.
9
H
G
B
(
g
/
L
)
1
2
8
.
5
7
±
5
1
2
0
6
.
3
3
±
3
7
1
7
1
.
5
0
±
1
8
1
3
3
.
6
7
±
4
3
1
2
0
.
0
0
±
1
2
2
0
3
.
0
0
±
6
7
1
2
2
.
2
9
±
2
7
2
0
5
.
3
3
±
2
1
1
7
3
.
8
3
±
1
7
1
3
2
.
0
±
6
1
2
9
.
0
±
1
2
2
1
6
.
0
±
2
2
H
C
T
(
%
)
3
5
.
5
3
±
8
.
8
2
5
8
.
7
5
±
5
0
.
8
4
9
.
8
5
±
4
2
.
2
3
6
.
0
0
±
3
.
6
3
1
.
8
±
0
.
3
4
9
.
1
0
±
2
2
.
5
3
4
.
4
±
2
6
.
5
5
7
.
6
1
±
2
2
.
6
4
9
.
1
2
±
6
.
1
3
4
.
7
7
±
1
.
2
3
4
.
6
3
±
0
.
1
5
2
.
2
3
±
4
4
M
C
V
(
1
0
−
1
5
L
)
5
2
.
0
3
±
3
.
6
5
1
.
5
8
±
5
.
1
5
1
.
0
5
±
2
.
9
3
5
1
.
9
7
±
2
.
9
5
2
.
4
3
±
0
.
9
5
3
.
2
0
±
3
.
9
5
1
.
5
3
±
4
.
1
4
9
.
3
5
±
4
.
1
4
9
.
3
5
±
1
.
8
5
0
.
2
7
±
3
.
6
5
1
.
6
7
±
2
.
6
5
1
.
7
3
±
7
.
8
M
C
H
(
1
0
−
1
2
g
)
1
8
.
8
7
±
1
.
3
1
7
.
6
3
±
1
.
0
1
7
.
5
3
±
0
.
6
1
9
.
2
8
±
0
.
6
1
9
.
8
0
±
0
.
1
2
2
.
1
0
±
3
.
7
1
9
.
4
0
±
2
.
9
1
7
.
6
3
±
1
.
0
1
7
.
5
0
±
0
.
7
1
9
.
0
8
±
0
.
4
1
9
.
2
3
±
0
.
3
2
1
.
5
3
±
3
.
9
P
L
T
(
1
0
9
/
L
)
2
3
9
.
6
±
3
4
.
6
1
2
9
.
0
±
2
6
2
4
7
.
3
±
2
7
.
5
1
7
3
.
5
±
2
3
.
1
2
6
0
.
7
±
4
2
.
3
1
9
5
.
6
±
7
6
.
3
2
6
4
.
8
±
4
7
.
3
1
2
0
.
8
±
2
2
.
1
2
6
7
.
1
±
1
1
.
5
1
8
4
.
2
±
2
0
2
6
5
.
3
±
7
6
2
1
7
.
0
±
2
0
A
L
T
(
U
/
L
)
5
9
.
0
±
0
.
7
8
7
.
5
±
3
0
.
5
6
9
.
1
7
±
2
9
.
9
7
6
.
1
7
±
2
4
.
6
5
9
.
6
7
±
2
7
.
5
6
4
.
0
0
±
4
3
5
1
.
2
5
±
0
.
9
7
0
.
5
0
±
2
0
.
3
6
8
.
3
3
±
2
7
7
5
.
3
±
2
9
.
4
5
9
.
2
±
2
4
.
1
5
7
.
3
3
±
4
1
A
L
P
(
U
/
L
)
2
3
2
.
7
9
±
3
.
9
2
3
4
.
0
0
±
3
.
8
2
4
7
.
6
±
1
4
.
8
2
4
9
.
3
±
2
7
.
5
2
4
8
.
3
±
1
3
.
8
2
4
9
.
2
±
1
4
.
2
2
3
2
.
2
1
±
4
.
9
2
3
8
.
1
7
±
5
.
7
2
4
6
.
6
±
1
5
.
9
2
4
7
.
3
±
1
5
2
4
6
.
1
±
1
3
2
4
7
.
6
±
1
7
∗
T
h
e
N
u
-
3
c
o
n
c
e
n
t
r
a
t
i
o
n
w
a
s
1
0
0
m
g
/
m
l
.
T
h
e
d
a
t
a
w
e
r
e
e
x
p
r
e
s
s
e
d
a
s
a
v
e
r
a
g
e
±
S
D
.Journal of Biomedicine and Biotechnology 7
400
410
420
430
440
450
460
470
−1 7 14 21 28
B
o
d
y
w
e
i
g
h
t
(
g
)
(days)
(a)
0
10
20
30
40
50
60
70
1 3 5 7 9 1 11 31 51 71 92 12 32 52 7
W
a
t
e
r
u
p
t
a
k
e
(
m
L
)
(days)
(b)
10
15
20
25
30
35
40
3 6 9 12 15 18 21 24 27
F
o
o
d
u
p
t
a
k
e
(
g
)
Nu-3
Control
(days)
(c)
Figure 4: Clinical observations after repeated dermal doses of Nu-3
for 28 days. (a) Body weight; (b) water uptake; (c) food uptake.
nonactivated assays in the dose range from 0–1000μg/ml.
However, at a very high concentration (2000μg/mL) there
appeared to have an increase in mutation frequency, which
suggested a weak positive response.
3.6. In Vivo Mouse Micronucleus Assay. The percentage
of PCE and NCE of the erythrocytic lines in the Nu-3-
treated groups were not signiﬁcantly diﬀerent from that in
the control group. The numbers of micronucleated PCE
in all the groups were shown in Table 5.T h e r ew a sa
Table 4: CHO/HGPRT mutation assay.
Mutation frequency (mutants/1×106 clonable cells)
Groups Activated Nonactivated
Saline control 3.30 3.30
Positive control 244.0 187.0
Nu-3 (500μg/ml) 5.40 4.50
Nu-3 (1000μg/ml) 4.50 5.70
Nu-3 (2000μg/ml) 6.90 8.30
signiﬁcant diﬀerence in the numbers of micronucleated PCE
between the positive control group and all Nu-3 treated
groups (P<.01) and between the high dosing group and the
negative control (P<.03). However, there was no signiﬁcant
diﬀerence between the two low-dosing groups and the
negative control group (P>.05). In all the test groups, the
PCE numbers were almost same between the males and
females. These results indicated that at low and medium
dosages, Nu-3 caused no evident cytotoxicity. At a very high
dose (1000mg/kg), an increase in the PCEs with absolute
values outside the normal control levels (i.e., 0.3%–0.4%)
was observed, suggestive of a weak genotoxic potential for
Nu-3.
4. Discussion
Antibiotic drug development has failed to keep pace with
the numbers of emerging antibiotic resistant strains and
variants. Consequently, the past decade has seen the emer-
gence of the widely publicized health crisis where the
means to combat drug-resistant, plague bacteria and viral
pandemics are failing. Thus, the healthcare community
is desperate for new therapeutics. Nu-3 is a novel small
molecule and has been examined in several studies for its
antibacterial and therapeutic action, showing that it was
as eﬀective as intravenously administered ciproﬂoxacin, a
potent and broadspectrum ﬂuoroquinolone [11]. However,
there is still lack of toxicological data for Nubiotics. In this
study, we reported that Nu-3 is hypotoxical by intragastric
administration. In the repeated dermal toxicity test, there
was no chronic toxicity given by external application. The
irritation study on cutis and mucosa revealed that Nu-3 did
not irritate the skin tissue. Further studies demonstrated that
Nu-3 had no notable genetic toxicity both in vitro and in
vivo. Taken together, our data suggested that Nu-3 is a well
tolerated and exhibited no toxicity when administrated via
intragastric and topical routes.
Chemically, Nu-3 is a modiﬁed nucleotide, which could
potentially cause genetic mutations in the target tissues
through disrupting DNA or RNA replication/transcription.
To examine if this is the case for Nu-3, the golden standard
assays in cells and animals were performed and found
no meaningful mutational eﬀect on the testing subjects.
Three reasons may account for our observations. First, Nu-
3 is a modiﬁed thymidine (butyl-phosphate-5 -thymidine-
3 -phosphate-butyl). It is unlikely that Nu-3 could compete
with dTTP in the cellular environment to be incorporated8 Journal of Biomedicine and Biotechnology
Table 5: The numbers of micronucleated PCE of in vivo mouse micronucleus Assay.
Groups Dose No. of Rats No. of
PEC/Rat
♂ (5) ♀ (5)
No. of
micronucleated
PCE
Rate∗ of
micronucleated
PCE (%)
No. of
micronucleated
PCE
Rate of
micronucleated
PCE (%)
1 1000mg/kg Nu-3 10 2000 18±2.5 0.9 20±0.5 1.0
2 500mg/kg Nu-3 10 2000 8±0.5 0.4 8±0.5 0.4
3 25mg/kg Nu-3 10 2000 7±1.5 0.35 8±0.5 0.4
4 Saline 10 2000 6±1.5 0.3 7±0.5 0.35
5 Cyclophosphamide 10 2000 58±2.5 2.9 60±0.5 3.0
∗The rate was calculated with the number of polychromatic erythrocytes (PCEs) that contained at least one micronucleus divided by 2000.
into DNA during replication. Second, although the antibac-
terialactivitiesofNu-3havebeendemonstratedbothinvitro
and in vivo, its mechanism of action is still not clear. One
of the possible mechanisms for Nu-3 action has recently
been proposed, which was supported by the preliminary
data showing that Nu-3 caused signiﬁcant changes of the
membrane polarity. This change led to the disruption of
the bacterial membrane. Lastly, the pharmacological data
indicated that the bioavailability and PK proﬁle of Nu-3
were similar to those from other nucleoside drugs, which
supports the notion of its hypotoxicity for pharmaceutical
use (unpublished data). Thus, we suggest that the lack of
genotoxicity of Nu-3 observed in this study may be due to
its unique feature of the mechanisms of action.
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